Search

Your search keyword '"Rubinsak J"' showing total 6 results
Start Over Author "Rubinsak J"
6 results on '"Rubinsak J"'

1. An open-label randomized phase II trial of belinostat (PXD101) in combination with carboplatin and paclitaxel (BelCaP) compared to carboplatin and paclitaxel in patients with previously untreated carcinoma of unknown primary.

Author

Daugaard, G., primary, Fizazi, K., additional, Huebner, G., additional, Braumann, D., additional, Rubinsak, J. R., additional, Allouache, D., additional, Rodriguez, G. I., additional, Stahl, M., additional, Fuglsang, L., additional, and Hainsworth, J. D., additional

Published
2010
Full Text
View/download PDF

6. Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulfan/cyclophosphamide.

Author

Essell JH, Thompson JM, Harman GS, Halvorson RD, Snyder MJ, Johnson RA, and Rubinsak JR

Subjects
Actuarial Analysis, Adult, Bone Marrow Transplantation methods, Busulfan adverse effects, Female, Follow-Up Studies, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive surgery, Leukemia, Myeloid, Acute surgery, Male, Methylprednisolone adverse effects, Precursor Cell Lymphoblastic Leukemia-Lymphoma surgery, Time Factors, Whole-Body Irradiation, Bone Marrow Transplantation immunology, Busulfan therapeutic use, Cyclophosphamide therapeutic use, Graft vs Host Disease prevention & control, Hepatic Veno-Occlusive Disease chemically induced, Leukemia surgery, Methotrexate adverse effects, Methotrexate therapeutic use, Methylprednisolone therapeutic use
Abstract

The use of cyclosporine-A/methotrexate (CyA/MTX) for graft-versus-host disease (GVHD) prophylaxis is safe and effective for patients undergoing allogeneic bone marrow transplantation after preparation with cyclophosphamide and total body irradiation. We report 87 patients prepared for allogeneic transplant with busulfan 4 mg/kg/d orally for 4 days, followed by cyclophosphamide 60 mg/kg/d intravenously for 2 days (Bu4Cy2). A marked increase in hepatotoxicity was observed in 20 patients administered CyA/MTX, compared with 67 historical control patients who received CyA/methylprednisolone (CyA/MP) for GVHD prophylaxis with all other treatment and support variables remaining constant. The incidence of hyperbilirubinemia (bilirubin greater than or equal to 2 mg/dL) increased from 48% to 80% (P = .02), and the mean maximal bilirubin increased from 4.67 +/- 7.27 to 8.72 +/- 8.73 mg/dL (P = .04), when CyA/MTX was used in place of CyA/MP for GVHD prophylaxis. In addition, the incidence of veno-occlusive disease (VOD) increased from 18% to 70% (P = .0001), and death caused by VOD increased from 4.5% to 25% (P = .02). Survival was not significantly different for the two groups because of a higher non-VOD death rate in patients receiving CyA/MP for GVHD prophylaxis (P = .77). We suggest caution when using Bu4Cy2 in combination with CyA/MTX for GVHD prophylaxis.

Published
1992

Catalog

Books, media, physical & digital resources
See catalog results